Hideo Hagihara
Overview
Explore the profile of Hideo Hagihara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
787
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naganishi S, Hagihara H, Miyakawa T
Neuropsychopharmacol Rep
. 2025 Feb;
45(1):e70001.
PMID: 39907034
Aims: Alzheimer's disease (AD) is a leading cause of dementia, with increasing prevalence. Mutations in genes like MAPT, PSEN1, and PSEN2 are risk factors, leading to the development of several...
2.
Hagihara H, Miyakawa T
Transl Psychiatry
. 2024 Nov;
14(1):460.
PMID: 39496593
Introduction: Major depressive disorder (MDD) is a prevalent and debilitating mental disorder that shares symptoms, genetics, and molecular changes in the brain with other psychiatric disorders, such as schizophrenia and...
3.
Hagihara H, Miyakawa T
Int J Neuropsychopharmacol
. 2024 Oct;
27(10).
PMID: 39422361
Background: Altered brain energy metabolism is implicated in Alzheimer disease (AD). Limited and conflicting studies on brain pH changes, indicative of metabolic alterations associated with neural activity, warrant a comprehensive...
4.
Hagihara H, Shoji H, Hattori S, Sala G, Takamiya Y, Tanaka M, et al.
Elife
. 2024 Mar;
12.
PMID: 38529532
Increased levels of lactate, an end-product of glycolysis, have been proposed as a potential surrogate marker for metabolic changes during neuronal excitation. These changes in lactate levels can result in...
5.
Temma Y, Obi-Nagata K, Hoshiba Y, Miyake R, Katayama Y, Hagihara H, et al.
Front Psychiatry
. 2023 Dec;
14:1277097.
PMID: 38094594
Major depressive disorder (depression) is a leading cause of disability. The severity of depression is affected by many factors, one of which being comorbidity with diabetes mellitus (DM). The comorbidity...
6.
Oishi K, Yajima Y, Yoshida Y, Hagihara H, Miyakawa T, Higo-Yamamoto S, et al.
Sci Rep
. 2023 Jul;
13(1):11156.
PMID: 37429932
Disordered sleep is a global social problem and an established significant risk factor for psychological and metabolic diseases. We profiled non-targeted metabolites in saliva from mouse models of chronic sleep...
7.
Hagihara H, Murano T, Miyakawa T
Front Psychiatry
. 2023 May;
14:1151480.
PMID: 37200901
Hydrogen ion (H) is one of the most potent intrinsic neuromodulators in the brain in terms of concentration. Changes in H concentration, expressed as pH, are thought to be associated...
8.
Hagihara H, Shoji H, Kuroiwa M, Graef I, Crabtree G, Nishi A, et al.
Mol Brain
. 2022 Nov;
15(1):94.
PMID: 36414974
Calcineurin (Cn), a phosphatase important for synaptic plasticity and neuronal development, has been implicated in the etiology and pathophysiology of neuropsychiatric disorders, including schizophrenia, intellectual disability, autism spectrum disorders, epilepsy,...
9.
Nagai M, Iemura K, Kikkawa T, Naher S, Hattori S, Hagihara H, et al.
Brain Commun
. 2022 Sep;
4(5):fcac220.
PMID: 36106092
is a gene associated with intellectual disability, which was originally identified as being involved in the maintenance of kinetochore-microtubule attachment. To explore the neuronal defects caused by deficiency, we established...
10.
Sato D, Inoue Y, Kuga N, Hattori S, Nomoto K, Morimoto Y, et al.
iScience
. 2022 Aug;
25(8):104800.
PMID: 35992083
The human vesicular monoamine transporter 1 () harbors unique substitutions (Asn136Thr/Ile) that affect monoamine uptake into synaptic vesicles. These substitutions are absent in all known mammals, suggesting their contributions to...